After the COVID-19 epidemic, drug shortages, pressure on drug prices and geopolitical risks in the supply chain continue to emphasize the importance of flexible manufacturing and stable supply chain, and raise the awareness of risks in the biopharmaceutical CDMO (Contract Development and Manufacturing Organization) supply chain distribution. The new version of the BIOSECURE Act is gradually building up the defense of biopharmaceuticals and raising the uncertainty of the supply chain! The bill mainly prevents the outflow of core data of U.S. biopharmaceutical research and development, and restricts the dealings with Chinese biopharmaceutical companies, so will the U.S. biopharmaceutical industry and China's CDMOs embark on the path of decoupling? Has become the international CDMO continued focus of attention, the bill seems to let the European, Korean, Japanese and Taiwanese CDMO manufacturers smell the CDMO re-order business opportunities, the future will certainly lead to changes in the CDMO supply chain landscape.